All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network

The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Is pacritinib safe and efficacious for patients with MF who failed ruxolitinib?

Featured
Jan 20, 2020
Share:

The MPN Hub were pleased to speak to Aaron Gerds, Cleveland Clinic Taussig Cancer Institute, Cleveland, US, during the 61st American Society of Hematology (ASH) meeting in Orlando, US. We asked: Could pacritinib represent a new efficacious treatment for patients with myelofibrosis who have failed ruxolitinib?

Aaron Gerds discusses the PAC203 study that evaluated the efficacy of the JAK inhibitor, pacritinib, in patients with myelofibrosis and low platelet counts, he talks about the patient characteristics, the optimal dose, safety, response rates and overall outcomes of patients. He also discusses the place of pacritinib in the treatment pathway and its effect on patient outcomes.

Is pacritinib safe and efficacious for patients with MF who failed ruxolitinib?

Share: